Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet medical needs.
Acer's lead drug candidate, EDSIVO for the treatment of orphan disease called vEDS, has an upcoming PDUFA date on June 25, 2019. Typically, investors would expect the share price of Acer to increase leading up to the PDUFA date in anticipation of the drug's approval by the FDA. Instead, as can be seen by the 3-month